公开(公告)号：US09572837B2

公开(公告)日：2017-02-21

申请号：US15093643

申请日：2016-04-07

Applicant: SiDanSai Biotechnology CO.,LTD

Inventor： Zhao Wu

IPC: A61K35/26 ,  C12N5/10 ,  C07K14/705 ,  A61K35/17 ,  C07K16/30 ,  C12N5/0783 ,  C07K16/28 ,  A61K39/00

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61K39/0011 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2803 ,  C07K16/30 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0638 ,  C12N2510/02

Abstract: The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).

Abstract translation: 本公开涉及用于降低与CAR T细胞治疗相关的免疫耐受性的组合物和方法。 本公开的实施方案包括分离的核酸序列，其包含编码修饰的程序性细胞死亡蛋白1（PD-1）的核酸序列和编码嵌合抗原受体（CAR）的核酸序列。

公开(公告)号：US20170044587A1

公开(公告)日：2017-02-16

申请号：US15307389

申请日：2015-04-29

Applicant: NOVARTIS AG

Inventor： Holger Laux ,  Sandrine Romand ,  Ursula Bodendorf

IPC: C12P21/00 ,  G01N15/14 ,  C12N5/00 ,  C12N9/64

CPC classification number: C12P21/00 ,  C12N5/00 ,  C12N9/6424 ,  C12N15/907 ,  C12N2510/02 ,  C12Y304/21109 ,  G01N15/14 ,  G01N2015/0065 ,  G01N2015/1006

Abstract: The present application pertains inter alia to an isolated vertebrate cell suitable for recombinant expression of a polypeptide of interest, wherein the vertebrate cell is altered to impair the function of the endogenous protease matriptase and wherein said cell comprises at least one heterologous polynucleotide encoding a polypeptide of interest and wherein the polypeptide of interest is secreted by the cell. It was found that using respective vertebrate cells for producing a recombinant polypeptide of interest significantly reduces clipping of the polypeptide of interest that is secreted into the cell culture medium. Also provided are improved production and screening methods.

Abstract translation: 本申请特别涉及适合于重组表达感兴趣的多肽的分离的脊椎动物细胞，其中改变脊椎动物细胞以损害内源性蛋白酶基序酶的功能，并且其中所述细胞包含至少一种异源多核苷酸，其编码多肽 感兴趣并且其中感兴趣的多肽由细胞分泌。 已经发现，使用相应的脊椎动物细胞来产生感兴趣的重组多肽显着减少分泌到细胞培养基中的目的多肽的剪切。 还提供了改进的生产和筛选方法。

公开(公告)号：US20170016043A1

公开(公告)日：2017-01-19

申请号：US15209695

申请日：2016-07-13

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Jonathan ZMUDA ,  Chao Yan LIU

IPC: C12P21/02 ,  C07K14/505 ,  C07K16/00

CPC classification number: C12P21/02 ,  C07K14/505 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/92 ,  C12N5/0043 ,  C12N2510/02 ,  C12N2511/00

Abstract: The present invention is directed generally to systems and methods suitable for high level expression of recombinant proteins in suspension CHO cells. In particular, the invention allows introduction of the invention obviates the need to replace, replenish or supplement the growth medium during the procedure. The invention also relates to compositions and kits useful for culturing and transforming/transfecting suspension CHO cells.

Abstract translation: 本发明一般涉及适用于悬浮CHO细胞中重组蛋白高水平表达的系统和方法。 特别地，本发明允许本发明的引入消除了在该过程期间更换，补充或补充生长培养基的需要。 本发明还涉及可用于培养和转化/转染悬浮液CHO细胞的组合物和试剂盒。

公开(公告)号：US09512200B2

公开(公告)日：2016-12-06

申请号：US13342704

申请日：2012-01-03

Applicant: Theresa A. Deisher

Inventor： Theresa A. Deisher

IPC: C12N5/074 ,  A61K38/00 ,  A61K39/00 ,  C07K14/00 ,  C07K16/00 ,  A61K35/545

CPC classification number: C12N5/0696 ,  A61K35/545 ,  A61K38/00 ,  A61K39/00 ,  C07K14/00 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/41 ,  C12N2510/02 ,  C12N2517/04

Abstract: The invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic acid(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stem cells to be re-differentiated towards their somatic cell of origin so that the cells can be used to therapeutically treat an animal without resulting teratoma formation.

Abstract translation: 本发明提供了用生物制品处理的动物中产生具有降低的抗原性水平的多肽蛋白产物和核酸产物的方法。 将体细胞从动物中分离，转化成用目标核酸转染的多能干细胞，并再次分化为已知是所需核酸产物的高水平生产者的体细胞。 本发明可用于衍生一般细胞系以治疗群体，种族特异性细胞系以治疗种族群体或患者特异性细胞系以治疗个体。 另外，本发明提供了允许诱导的多能干细胞对其体细胞原体再分化的方法，使得细胞可用于治疗性处理动物而不导致畸胎瘤形成。

公开(公告)号：US20160326249A1

公开(公告)日：2016-11-10

申请号：US15109709

申请日：2015-01-15

Applicant: ZYMEWORKS INC.

Inventor： Gordon Yiu Kon Ng ,  Thomas Spreter von Kreudenstein ,  Leonard G. Presta

IPC: C07K16/28

CPC classification number: C07K16/2809 ,  A61K39/39541 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C12N2510/02

Abstract: Antigen-binding constructs, e.g., antibodies, which bind CD3 and CD 19 and methods of use are disclosed.

Abstract translation: 公开了结合CD3和CD19的抗原结合构建体，例如抗体及其使用方法。

公开(公告)号：US09476027B2

公开(公告)日：2016-10-25

申请号：US12972290

申请日：2010-12-17

Applicant: Roland Buelow

Inventor： Roland Buelow

IPC: A01K67/00 ,  A01K67/027 ,  C12N15/00 ,  C07H21/04 ,  C12N5/0781 ,  A61K39/00 ,  C07K14/705 ,  C09K5/04 ,  C12N15/85 ,  C12N15/79

CPC classification number: C12N5/0635 ,  A01K67/0275 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/072 ,  A01K2227/107 ,  A01K2267/01 ,  A61K39/00 ,  C07H21/04 ,  C07K14/70503 ,  C09K5/045 ,  C09K2205/126 ,  C12N15/79 ,  C12N15/85 ,  C12N15/8509 ,  C12N2510/02 ,  C12N2510/04 ,  C12N2517/02

Abstract: The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Igα and/or Igβ sequences. Of particular interest are animals with transgenic heavy and light chain immunoglobulin loci capable of producing a diversified human(ized) antibody repertoire that have their endogenous production of Ig and/or endogenous Igα and/or Igβ sequences suppressed. Simultaneous expression of human(ized) immunoglobulin and human(ized) Igα and/or Igβ results in normal B-cell development, affinity maturation and efficient expression of human(ized) antibodies.

Abstract translation: 本发明描述了具有编码人（Ig）和/或Igβ序列的人（免疫球蛋白）免疫球蛋白基因座和转基因的转基因动物。 特别令人感兴趣的是具有转录重链和轻链免疫球蛋白基因座的动物，能够产生具有内源性产生Ig和/或内源性Igα和/或Igβ序列的多种人（抗体）抗体库。 人类免疫球蛋白和人类Igα和/或Igβ的同时表达导致人类抗体的正常B细胞​​发育，亲和力成熟和有效表达。

公开(公告)号：US09465030B2

公开(公告)日：2016-10-11

申请号：US14408883

申请日：2013-06-17

Applicant: NATIONAL CANCER CENTER ,  LSIP, LLC

Inventor： Tetsuya Nakatsura ,  Keigo Saito

IPC: G01N33/577 ,  C07K16/18 ,  G01N33/574 ,  C07K16/30 ,  C12N5/16 ,  C07K16/22

CPC classification number: G01N33/5743 ,  C07K16/18 ,  C07K16/22 ,  C07K16/303 ,  C07K16/3053 ,  C07K2319/00 ,  C12N5/16 ,  C12N2510/02 ,  G01N33/577 ,  G01N2333/4722 ,  G01N2333/4727

Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.

Abstract translation: 提供了用于以高再现性诊断的试剂盒，所述试剂盒通过制备针对GPC3的单克隆抗体和针对SPARC的单克隆抗体而产生，其针对市售和常用抗体的质量稳定性优异，并且使用这些抗体。

公开(公告)号：US20160289637A1

公开(公告)日：2016-10-06

申请号：US15161213

申请日：2016-05-21

Applicant: Dana-Farber Cancer Institute, Inc.

Inventor： Michael GOLDBERG ,  Vera GREINER

IPC: C12N5/0781 ,  C12N15/90 ,  C07K16/24 ,  C12N15/10

CPC classification number: C12N5/0635 ,  A61K2039/5156 ,  C07K16/241 ,  C07K2317/21 ,  C07K2317/76 ,  C12N15/102 ,  C12N15/907 ,  C12N2310/20 ,  C12N2501/48 ,  C12N2510/02 ,  C12N2800/80 ,  C12Q2521/301

Abstract: The present invention provides methods compositions and methods of preparing autologous (or allogeneic) B cells that secrete a monoclonal of interest useful in immunotherapy or B cells with an altered function.

Abstract translation: 本发明提供了方法组合物和方法，其制备分泌具有改变功能的免疫疗法中可用的感兴趣的单克隆抗体的自体（或同种异体）B细胞。

公开(公告)号：US20160281106A1

公开(公告)日：2016-09-29

申请号：US15027929

申请日：2014-10-07

Applicant: PRESTIGE BIOPHARMA PTE. LTD.

Inventor： Soo Kwang Kim ,  Young Min Kim ,  Yong Gyu Son ,  Yong Ho Ahn ,  Dong Heon Lee ,  Yang Soon Lee ,  Hee Jung Jun ,  Yu Bin Choi ,  Eun A Kim

IPC: C12N15/85 ,  C07K16/24 ,  C07K16/28 ,  C07K16/18 ,  C07K1/14 ,  C07K16/22

CPC classification number: C12N15/85 ,  C07K1/14 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/24 ,  C07K16/241 ,  C07K16/244 ,  C07K16/2818 ,  C07K16/2866 ,  C12N2510/02 ,  C12N2840/203

Abstract: The present invention relates to a bicistronic expression vector for antibody expression, an animal cell transfected with the expression vector, and a method for producing an antibody including culturing the animal cell, in which the expression vector includes a first expression cassette including ‘promoter-UTR-intron-antibody light chain gene-polyA’ and a second expression cassette including ‘promoter-UTR-intron-antibody heavy chain gene-internal ribosome entry site (IRES)-amplification gene-polyA’. An expression vector capable of expressing a desired antibody with high efficiency can be constructed using the bicistronic expression vector including an intron for antibody expression according to the present invention, and the expression vector can produce the antibody by culturing the transfected animal cell with stability and high efficiency.

Abstract translation: 本发明涉及用于抗体表达的双顺反子表达载体，用表达载体转染的动物细胞，以及产生包含培养动物细胞的抗体的方法，其中表达载体包括第一表达盒，其包含“启动子-UTR - 内含子 - 抗体轻链基因-olyA'和包含“启动子-UTR内含子 - 抗体重链基因内部核糖体进入位点（IRES）扩增基因-GAA”的第二表达盒。 可以使用包含根据本发明的抗体表达的内含子的双顺反子表达载体构建能够高效表达所需抗体的表达载体，并且表达载体可以通过以稳定和高的方式培养转染的动物细胞来产生抗体 效率。

公开(公告)号：US20160264940A1

公开(公告)日：2016-09-15

申请号：US15028989

申请日：2014-04-03

Applicant: ARES TRADING S.A.

Inventor： HERVE BROLY ,  MATTHIEU STETTLER ,  MARTIN JORDAN ,  ARNAUD PERILLEUX ,  YOLANDE ROUILLER

IPC: C12N5/071 ,  C12N5/00

CPC classification number: C12N5/0682 ,  C12N5/0031 ,  C12N5/0037 ,  C12N5/005 ,  C12N5/16 ,  C12N2500/12 ,  C12N2500/14 ,  C12N2500/16 ,  C12N2500/22 ,  C12N2500/24 ,  C12N2500/32 ,  C12N2500/35 ,  C12N2500/38 ,  C12N2500/40 ,  C12N2500/46 ,  C12N2500/60 ,  C12N2500/90 ,  C12N2500/95 ,  C12N2500/99 ,  C12N2510/02

Abstract: The present invention relates to new serum- and protein-free culture media. These media are high performance culture media, which notably improve mammalian fed-batch cultures. The present invention also relates to methods for preparing and/or designing the medium, and methods of use thereof.

Abstract translation: 本发明涉及新的无血清和蛋白质的培养基。 这些培养基是高性能培养基，其显着地改善哺乳动物补料分批培养。 本发明还涉及用于制备和/或设计该介质的方法及其使用方法。